Connect Biopharma (CNTB)

Company Profile

suzhou connect biopharmaceuticals, ltd. is a pharmaceuticals company based out of 10th floor, xiangtang development building, #3 chaoyang dong rd, taicang, china.

Company profile

Ticker

CNTB

Exchange

Website

Incorporated

Location

Fiscal year end

Sector

Professional, Scientific, and Technical Services > Research and Development in Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies • Celgene ...

SEC CIK

0001835268

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

CNTB stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

6-K

Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update

12 Sep 23

6-K

Current report (foreign)

Correspondence with SEC

24 Jul 23

6-K

Current report (foreign)

Current report (foreign)

5 Jun 23

6-K

Current report (foreign)

1 Jun 23

6-K

Connect Biopharma Reports Full Year 2022 Financial Results

11 Apr 23

Transcripts

CNTB

Earnings call transcript

2022 Q2

14 Sep 22

Latest ownership filings

View all

SC 13G/A

Qiming Venture Partners V, L.P.

14 Feb 23

SC 13G

Shanghai Minhui Enterprise Management Consulting Partnership (Limited Partnership)

Advantech Capital II L.P.

15 Feb 22

SC 13G

Qiming Venture Partners VII, L.P.

14 Feb 22

Financial summary

Financial statements Chart CNTB financial data

Quarter (USD)	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q2 2023

CNTB institutional ownership history Ownership history

64.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	22	22	–
Opened positions	2	0	NEW
Closed positions	2	5	-60.0%
Increased positions	2	3	-33.3%
Reduced positions	6	6	–

13F shares	Current	Prev Q	Change
Total value	11.62 bn	10.87 bn	+6.9%
Total shares	35.53 mm	36.09 mm	-1.6%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Ra Capital Management	6.99 mm	$7.90 bn	0.0%
BioFortune	5.89 mm	$0.00	0.0%
Shanghai Minhui Enterprise Management Consulting Partnership	5.31 mm	$0.00	0.0%
Advantech Capital II	4.76 mm	$24.53 mm	0.0%
Qiming Venture Partners V	3.20 mm	$0.00	0.0%
Qiming Venture Partners VII	3.20 mm	$16.47 mm	0.0%
Huang James	2.82 mm	$2.16 mm	0.0%
BLK Blackrock	1.13 mm	$1.27 bn	0.0%
Adage Capital Partners GP, L.L.C.	650.00 k	$734.50 mm	-36.7%
Ubs Oconnor	603.90 k	$670.33 mm	+5.2%

Largest transactions	Shares	Bought/sold	Change
Adage Capital Partners GP, L.L.C.	650.00 k	-377.52 k	-36.7%
Kynam Capital Management	535.01 k	-204.64 k	-27.7%
JPM JPMorgan Chase & Co.	48.37 k	-30.18 k	-38.4%
Ubs Oconnor	603.90 k	+29.75 k	+5.2%
Two Sigma Investments	23.59 k	+23.59 k	NEW
Susquehanna International	10.47 k	-10.20 k	-49.3%
Rhumbline Advisers	9.94 k	+9.94 k	NEW
UBS UBS Group AG - Registered Shares	0.00	-9.34 k	EXIT
Renaissance Technologies	95.50 k	+6.40 k	+7.2%
FMR	24.00	-9.00	-27.3%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.